Satriano Joseph, Cunard Robyn, Peterson Orjan W, Dousa Thomas, Gabbai Francis B, Blantz Roland C
Division of Nephrology-Hypertension, Univ. of California, San Diego and Veterans Affairs San Diego Healthcare System, 3350 La Jolla Village Drive, M.C. 9111-H, San Diego, CA 92161, USA.
Am J Physiol Renal Physiol. 2008 Apr;294(4):F795-800. doi: 10.1152/ajprenal.00392.2007. Epub 2008 Jan 16.
Agmatine, decarboxylated arginine, is produced in the kidney and can increase nephron and kidney filtration rate via renal vasodilatation and increases in plasma flow. This increase in filtration rate after agmatine is prevented by administration of nitric oxide synthase (NOS) inhibitors. In endothelial cells, agmatine-stimulated nitrite production is accompanied by induction of cytosolic calcium. NOS activity requires calcium for activation; however, the source of this calcium remains unknown. Ryanodine receptor (RyR) calcium-activated calcium release channels are present in the kidney cortex, and we evaluated if RyR contributes to the agmatine response. Agmatine microperfused into Bowman's space reversibly increases nephron filtration rate (SNGFR) by approximately 30%. cADP-ribose (cADPR) regulates RyR channel activity. Concurrent infusion of agmatine with the cADPR blocker 8-bromo-cADPR (2 microM) prevents the increase in filtration rate. Furthermore, direct activation of the RyR channel with ryanodine at agonist concentrations (5 microM) increases SNGFR, and, like agmatine, this increase is prevented by administration of N(G)-monomethyl-l-arginine, a nonselective NOS blocker. We demonstrate that agmatine does not elicit ADPR cyclase activity in vascular smooth muscle membranes and does not directly affect RyR calcium channel responses using sea urchin egg homogenates. These results imply interplay between endothelial cell cADPR/RyR/Ca(2+)/NO and the cADPR/RyR/Ca(2+) pathways in vascular smooth muscle cells in arterioles in the regulation of kidney filtration rate. In conclusion, we show that agmatine-induced effects require activation of cADPR and RyR calcium release channels for NO generation, vasodilation, and increased filtration rate.
胍丁胺,即脱羧精氨酸,在肾脏中产生,可通过肾血管舒张和增加血浆流量来提高肾单位和肾脏滤过率。一氧化氮合酶(NOS)抑制剂的给药可阻止胍丁胺给药后滤过率的这种增加。在内皮细胞中,胍丁胺刺激的亚硝酸盐产生伴随着胞质钙的诱导。NOS活性需要钙来激活;然而,这种钙的来源仍然未知。兰尼碱受体(RyR)钙激活钙释放通道存在于肾皮质中,我们评估了RyR是否有助于胍丁胺反应。微灌注到鲍曼囊中的胍丁胺可使肾单位滤过率(SNGFR)可逆性增加约30%。环ADP核糖(cADPR)调节RyR通道活性。同时输注胍丁胺和cADPR阻滞剂8-溴-cADPR(2 microM)可阻止滤过率的增加。此外,以激动剂浓度(5 microM)的兰尼碱直接激活RyR通道可增加SNGFR,并且与胍丁胺一样,这种增加可通过给予非选择性NOS阻滞剂N(G)-单甲基-L-精氨酸来阻止。我们证明,胍丁胺不会在血管平滑肌膜中引发ADPR环化酶活性,并且使用海胆卵匀浆不会直接影响RyR钙通道反应。这些结果表明,内皮细胞cADPR/RyR/Ca(2+)/NO与血管平滑肌细胞中cADPR/RyR/Ca(2+)途径在调节肾滤过率方面存在相互作用。总之,我们表明胍丁胺诱导的效应需要激活cADPR和RyR钙释放通道以产生NO、血管舒张和增加滤过率。